MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.83
+0.04
+0.59%
After Hours: 6.83 0 0.00% 16:59 05/17 EDT
OPEN
6.75
PREV CLOSE
6.79
HIGH
6.88
LOW
6.72
VOLUME
741.62K
TURNOVER
--
52 WEEK HIGH
9.23
52 WEEK LOW
4.960
MARKET CAP
674.18M
P/E (TTM)
-5.9844
1D
5D
1M
3M
1Y
5Y
The Ardelyx, Inc. (NASDAQ:ARDX) Analysts Have Been Trimming Their Sales Forecasts
The analysts covering Ardelyx, Inc. ( NASDAQ:ARDX ) delivered a dose of negativity to shareholders today, by making a...
Simply Wall St. · 4d ago
Revenue Downgrade: Here's What Analysts Forecast For Ardelyx, Inc. (NASDAQ:ARDX)
The analysts covering Ardelyx, Inc. ( NASDAQ:ARDX ) delivered a dose of negativity to shareholders today, by making a...
Simply Wall St. · 4d ago
Global Diverticulitis Drugs Market to Record Significant CAGR During 2021-2029; Increasing Gastrointestinal Diseases to Create Growth Opportunities for the Market
May 12, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Diverticulitis Drugs Market - Global Demand Analysis and Opportunity Outlook...
AmericaNewsHour · 5d ago
Irritable Bowel Syndrome Drugs Market Growth to Witness a Surge by Rise in Prevalence of the Disease with a Notable CAGR during 2020 - 2029
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Irritable Bowel Syndrome Drugs Market: Global Demand Analysis & Opportunity...
AmericaNewsHour · 05/07 13:33
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -6.25% and 498.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 14:35
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the first...
PR Newswire · 05/06 13:00
BRIEF-Ardelyx Reports Q1 Loss Per Share Of $0.34
reuters.com · 05/06 12:54
Ardelyx EPS misses by $0.01, beats on revenue
Ardelyx (ARDX): Q1 GAAP EPS of -$0.34 misses by $0.01.Revenue of $6.58M (+443.8% Y/Y) beats by $5.48M.Press Release
Seekingalpha · 05/06 12:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARDX stock price target is 13.71 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 90.52M
% Owned: 91.70%
Shares Outstanding: 98.71M
TypeInstitutionsShares
Increased
26
2.03M
New
12
2.16M
Decreased
20
908.38K
Sold Out
1
10.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Other
Susan Rodriguez
Other
David Rosenbaum
Director
Muna Bhanji
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Richard Rodgers
No Data
  • All
  • Financials
  • Insiders
More
About ARDX
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.